Evidence map›Paper›PMID 16166580›Full record

ArticleStroke2005

Neuroprotective properties of the natural vitamin E alpha-tocotrienol.

Savita Khanna, Sashwati Roy, Andrew Slivka, Tara K S Craft, Soma Chaki, Cameron Rink, Margaret A Notestine, A Courtney DeVries, Narasimham L Parinandi, Chandan K Sen

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in Stroke, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 96 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02581085 phase2active not recruitingnot on this mapstarted 2019, after this paper: background citation

Tocotrienol Against the Progression of End Stage Liver Disease

TypeinterventionalSponsorChandan SenRan2019 to 2028Enrolled70ConditionsEnd Stage Liver Disease, NASH - Nonalcoholic Steatohepatitis, NAFLD - Nonalcoholic Fatty Liver DiseaseArmsTocotrienol (TCT), Placebo
NCT04491383 phase2active not recruitingnot on this mapstarted 2021, after this paper: background citation

Tocotrienols in Parkinson's Disease (PD): A Pilot, Randomised, Placebo-controlled Trial

TypeinterventionalSponsorNational Neuroscience InstituteRan2021 to 2027Enrolled100ConditionsNeuro-Degenerative Disease, Parkinson DiseaseArmsTocovid Suprabio (HOV-12020), Placebo
3 · Its place in the literature

Who cites it

96 citing papers in PubMed, 1 synthesis or guideline pooled it, 227 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

36 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Savita KhannaDepartment of Surgery, The Ohio State University Medical Center, Columbus, Ohio, USA.
Sashwati Roy
Andrew Slivka
Tara K S Craft
Soma Chaki
Cameron Rink
Margaret A Notestine
A Courtney DeVries
Narasimham L Parinandi
Chandan K Sen
The Ohio State University · US

Funding

Vitamin E Neuroprotection: Novel Molecular MechanismsR01NS042617 · NINDS · OHIO STATE UNIVERSITY · PI SEN, CHANDAN K · 2002 to 2021
$3.9M
SOCIOBIOLOGICAL FACTORS IN EXPERIMENTAL STROKE OUTCOMER01NS040267 · NINDS · OHIO STATE UNIVERSITY · PI DEVRIES, ANNE COURTNEY · 2000 to 2004
$1.2M
NINDS NIH HHS NS40267NINDS NIH HHS NS42617NINDS NIH HHS R01 NS040267NINDS NIH HHS R01 NS042617
6 · The paper itself

Abstract

background and purposeThe current work is based on our previous finding that in neuronal cells, nmol/L concentrations of alpha-tocotrienol (TCT), but not alpha-tocopherol (TCP), blocked glutamate-induced death by suppressing early activation of c-Src kinase and 12-lipoxygenase.

methodsThe single neuron microinjection technique was used to compare the neuroprotective effects of TCT with that of the more widely known TCP. Stroke-dependent brain tissue damage was studied in 12-Lox-deficient mice and spontaneously hypertensive rats orally supplemented with TCT.

resultsSubattomole quantity of TCT, but not TCP, protected neurons from glutamate challenge. Pharmacological as well as genetic approaches revealed that 12-Lox is rapidly tyrosine phosphorylated in the glutamate-challenged neuron and that this phosphorylation is catalyzed by c-Src. 12-Lox-deficient mice were more resistant to stroke-induced brain injury than their wild-type controls. Oral supplementation of TCT to spontaneously hypertensive rats led to increased TCT levels in the brain. TCT-supplemented rats showed more protection against stroke-induced injury compared with matched controls. Such protection was associated with lower c-Src activation and 12-Lox phosphorylation at the stroke site.

conclusionsThe natural vitamin E, TCT, acts on key molecular checkpoints to protect against glutamate- and stroke-induced neurodegeneration.

Indexed as

AnimalsAntioxidantsArachidonate 12-LipoxygenaseBrainCell DeathCell LineCells, CulturedCell SurvivalCerebral CortexCSK Tyrosine-Protein KinaseFluoresceinsGlutamic AcidHippocampusImmunohistochemistryMaleMiceAntioxidantsArachidonate 12-LipoxygenaseCSK Tyrosine-Protein KinaseFluoresceinsfluoro jadeGlutamic AcidNeuroprotective AgentsOrganic ChemicalsProtein-Tyrosine KinasesProto-Oncogene Proteins pp60(c-src)src-Family Kinasestocotrienol, alphaTocotrienolsTyrosineVitamin E

Identifiers

PMID16166580
PMCPMC1829173
OpenAlexW2140605096

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.